Cough - Pipeline Review, H1 2018

  • ID: 4464945
  • Report
  • 91 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Conrig Pharma ApS
  • Develco Pharma Schweiz AG
  • GlaxoSmithKline Plc
  • Grunenthal GmbH
  • MORE
Cough - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H1 2018, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a common reflex action that aims to clear the throat of mucus or foreign irritants. Dry cough, chronic cough and whooping cough (also known as pertussis) are distinct types of cough. Symptoms include runny or stuffy nose, hoarseness, wheezing and shortness of breath, heartburn or a sour taste in mouth and rarely coughing up blood. The predisposing factors include asthma, chronic obstructive pulmonary disease, cigarette smoking, lung diseases such as bronchiectasis, interstitial lung disease, or tumors, lung infections such as pneumonia or acute bronchitis and allergic rhino sinusitis. Treatment includes cough suppressants, oral expectorants, and topical (externally applied) drugs.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Cough - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 7, 2, 10, 3 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Conrig Pharma ApS
  • Develco Pharma Schweiz AG
  • GlaxoSmithKline Plc
  • Grunenthal GmbH
  • MORE
Introduction

The Publisher's Report Coverage

Cough - Overview

Cough - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cough - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough - Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

AstraZeneca Plc

Bayer AG

Charleston Laboratories Inc

Conrig Pharma ApS

Daewoong Pharmaceutical Co Ltd

Develco Pharma Schweiz AG

GlaxoSmithKline Plc

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Merck & Co Inc

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

SolAeroMed Inc

Vernalis Plc

Cough - Drug Profiles

AX-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1817080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzonatate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bradanicline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-07 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

codeine + guaifenesin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1340 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2798745 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin + hydrocodone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrocodone bitartrate + Undisclosed drug - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lesogaberan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levodropropizine CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORB-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant maleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pemirolast potassium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHCA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1226 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cough - Dormant Projects

Cough - Discontinued Products

Cough - Product Development Milestones

Featured News & Press Releases

Oct 26, 2017: Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough

Oct 17, 2017: Menlo Therapeutics Expands its Management Team

Sep 21, 2017: Patara Pharmas Phase 2 Study Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Mediciney Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Medicine

Sep 18, 2017: BELLUS Health's BLU-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models

Sep 11, 2017: Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs

May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough

Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference

Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough

Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference

May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference

Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial

Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cough, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cough - Pipeline by Alitair Pharmaceuticals Inc, H1 2018

Cough - Pipeline by AstraZeneca Plc, H1 2018

Cough - Pipeline by Bayer AG, H1 2018

Cough - Pipeline by Charleston Laboratories Inc, H1 2018

Cough - Pipeline by Conrig Pharma ApS, H1 2018

Cough - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Cough - Pipeline by Develco Pharma Schweiz AG, H1 2018

Cough - Pipeline by GlaxoSmithKline Plc, H1 2018

Cough - Pipeline by Grunenthal GmbH, H1 2018

Cough - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018

Cough - Pipeline by Merck & Co Inc, H1 2018

Cough - Pipeline by Orbis Biosciences Inc, H1 2018

Cough - Pipeline by Patara Pharma Inc, H1 2018

Cough - Pipeline by PhytoHealth Corp, H1 2018

Cough - Pipeline by SolAeroMed Inc, H1 2018

Cough - Pipeline by Vernalis Plc, H1 2018

Cough - Dormant Projects, H1 2018

Cough - Dormant Projects, H1 2018 (Contd..1), H1 2018

Cough - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Cough, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alitair Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bayer AG
  • Charleston Laboratories Inc
  • Conrig Pharma ApS
  • Daewoong Pharmaceutical Co Ltd
  • Develco Pharma Schweiz AG
  • GlaxoSmithKline Plc
  • Grunenthal GmbH
  • Hyundai Pharmaceutical Co Ltd
  • M
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll